Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400603 | 0.86 | L3MBTL1 (0.58) | L3MBTL1LMNAMAPK1PTGS1MTNR1A | |
| SCHEMBL503788 | 0.86 | L3MBTL1 (0.58) | L3MBTL1LMNAMAPK1PTGS1MTNR1A | |
| SCHEMBL503789 | 0.86 | L3MBTL1 (0.58) | L3MBTL1LMNAMAPK1PTGS1MTNR1A | |
| Mandelic Acid SCHEMBL4873771 | 0.83 | ACHE (0.57) | LMNAMAPK1TRPM8 | |
| Mandelic Acid SCHEMBL2436177 | 0.83 | ACHE (0.57) | LMNAMAPK1TRPM8 | |
| SCHEMBL135107 | 0.83 | TAAR1 (0.56) | L3MBTL1AOC3CASR | |
| SCHEMBL335349 | 0.83 | TAAR1 (0.56) | L3MBTL1AOC3CASR | |
| SCHEMBL335622 | 0.83 | TAAR1 (0.56) | L3MBTL1AOC3CASR | |
| SCHEMBL29676707 | 0.83 | TAAR1 (0.56) | L3MBTL1AOC3CASR | |
| SCHEMBL29350839 | 0.83 | TAAR1 (0.56) | L3MBTL1AOC3CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230666-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | SHODHANA LABORATORIES LIMITED (IN) | 2011-09-22 | — | — | US | disclosed |
| WO-2011070585-A1 | PROCESSES FOR PREPARING RIVASTIGMINE, SALTS AND INTERMEDIATES THEREOF | SHODHANA LABORATORIES LIMITED (IN) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230666-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERICALLY PURE COMPOUNDS | HTR5A, ACHE, CHRNA5 | L3MBTL1 4233/4885LMNA 2205/4885MAPK1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.